Chimeric Antigen Receptor T-cell Therapy Associated Hemophagocytic Lymphohistiocytosis Syndrome: Clinical Presentation, Outcomes, and Management

Overview

Journal Blood Cancer J

Date 2024 Aug 12

PMID 39134524

Authors

Arushi Khurana

Allison C Rosenthal

Razan Mohty

Mamatha Gaddam

Radhika Bansal

Matthew A Hathcock

Adrienne N Nedved

Urshila Durani

Madiha Iqbal

Yucai Wang

Jonas Paludo

J C Villasboas

David Dingli

Taxiarchis Kourelis

Nelson Leung

Hassan Alkhateeb

Michael W Ruff

Alice Gallo de Moraes

Paschalis Vergidis

Joerg Herrmann

Saad S Kenderian

N Nora Bennani

Patrick B Johnston

Stephen M Ansell

Yi Lin

Affiliations

Soon will be listed here.

References

Singbartl K, Rosenthal A, Leis J, Patel B, Sen A . Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-A Case Report. Crit Care Explor. 2021; 3(7):e0472. PMC: 8245117. DOI: 10.1097/CCE.0000000000000472. View

Hines M, Knight T, McNerney K, Leick M, Jain T, Ahmed S . Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023; 29(7):438.e1-438.e16. PMC: 10330221. DOI: 10.1016/j.jtct.2023.03.006. View

Constantinescu C, Pasca S, Tat T, Teodorescu P, Vlad C, Iluta S . Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?. J Immunother Cancer. 2020; 8(1). PMC: 7264828. DOI: 10.1136/jitc-2020-000742. View

Hines M, Keenan C, Alfaro G, Cheng C, Zhou Y, Sharma A . Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021; 194(4):701-707. PMC: 8756350. DOI: 10.1111/bjh.17662. View

Lichtenstein D, Schischlik F, Shao L, Steinberg S, Yates B, Wang H . Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021; 138(24):2469-2484. PMC: 8832442. DOI: 10.1182/blood.2021011898. View

Hashmi H, Bachmeier C, Chavez J, Song J, Hussaini M, Krivenko G . Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Br J Haematol. 2019; 187(2):e35-e38. DOI: 10.1111/bjh.16155. View

La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N . Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019; 133(23):2465-2477. DOI: 10.1182/blood.2018894618. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Wehrli M, Gallagher K, Chen Y, Leick M, McAfee S, El-Jawahri A . Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022; 10(1). PMC: 8744112. DOI: 10.1136/jitc-2021-003847. View

10.

Shah N, Highfill S, Shalabi H, Yates B, Jin J, Wolters P . CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020; 38(17):1938-1950. PMC: 7280047. DOI: 10.1200/JCO.19.03279. View

11.

Sandler R, Tattersall R, Schoemans H, Greco R, Badoglio M, Labopin M . Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant.... Front Immunol. 2020; 11:524. PMC: 7137396. DOI: 10.3389/fimmu.2020.00524. View